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ABSTRACT
A wide range of human malignancies displays aberrant activation of Hedgehog 
(HH)/GLI signaling, including cancers of the skin, brain, gastrointestinal tract and 
hematopoietic system. Targeting oncogenic HH/GLI signaling with small molecule 
inhibitors of the essential pathway effector Smoothened (SMO) has shown remarkable 
therapeutic effects in patients with advanced and metastatic basal cell carcinoma. 
However, acquired and de novo resistance to SMO inhibitors poses severe limitations 
to the use of SMO antagonists and urgently calls for the identification of novel targets 
and compounds.
Here we report on the identification of the Dual-Specificity-Tyrosine-
Phosphorylation-Regulated Kinase 1B (DYRK1B) as critical positive regulator of 
HH/GLI signaling downstream of SMO. Genetic and chemical inhibition of DYRK1B 
in human and mouse cancer cells resulted in marked repression of HH signaling 
and GLI1 expression, respectively. Importantly, DYRK1B inhibition profoundly 
impaired GLI1 expression in both SMO-inhibitor sensitive and resistant settings. 
We further introduce a novel small molecule DYRK1B inhibitor, DYRKi, with suitable 
pharmacologic properties to impair SMO-dependent and SMO-independent oncogenic 
GLI activity. The results support the use of DYRK1B antagonists for the treatment 
of HH/GLI-associated cancers where SMO inhibitors fail to demonstrate therapeutic 
efficacy.
INTRODUCTION
The Hedgehog (HH)/GLI pathway plays a central 
role in the control of vertebrate development and tissue 
homeostasis of adult mammalian organisms, while its 
uncontrolled activation or inefficient termination has been 
implicated in a number of human malignancies including 
cancers of the skin, brain, hematopoietic system, lung, 
ovary and of the gastrointestinal tract [1]. Targeting 
oncogenic HH/GLI signaling in cancer and cancer stem 
cells has therefore emerged as promising therapeutic 
strategy for many malignant diseases with high medical 
need [2, 3].
Precise control of canonical HH/GLI signaling is an 
intricate process involving numerous regulatory processes. 
Briefly, in the absence of HH ligand, the twelve-
transmembrane protein Patched (PTCH) represses HH 
signaling by preventing the G-protein coupled receptor-
like protein Smoothened (SMO) to translocate to the 
primary cilium, an antenna-like compartment central to 
the activation of canonical HH/GLI signaling. Binding of 
HH to its receptor PTCH revokes the repressive effect of 
PTCH thereby allowing SMO to enter the primary cilium 
and initiate signaling. In the cilium, SMO activates the 
GLI zinc finger transcription factors GLI2/3 by preventing 
the formation of GLI repressor forms and by releasing 
GLIs from their negative regulator Suppressor of Fused 
(SUFU). Translocation of GLI2/3 activator forms to the 
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nucleus induces HH/GLI target gene expression, including 
the potent transcriptional activator and oncogene GLI1 
(for detailed reviews see [4-7]). 
The etiologic role of HH signaling in cancer has 
triggered numerous efforts to develop HH pathway 
antagonists targeting the essential HH effector SMO 
[8]. In 2012, the FDA approved vismodegib, a small 
molecule inhibitor of SMO, for the treatment of non-
melanoma skin cancer. Vismodegib provides a remarkable 
therapeutic benefit to patients with advanced or metastatic 
basal cell carcinoma (BCC) [3], a malignancy caused 
by loss of PTCH or mutational activation of SMO [9]. 
Despite several successful trials with BCC patients and 
case studies with medulloblastoma (MB) patients, the 
therapeutic efficacy of SMO targeting is challenged 
by acquired and de novo drug resistance [10-12]. 
Furthermore, clinical trials with SMO inhibitors so far 
have failed to prove a clear therapeutic benefit for patients 
with non-BCC malignancies including colorectal, ovarian 
and pancreatic cancer [13, 14].
De novo resistance to SMO targeting can – at least 
in part – be explained by the uncoupling of GLI activation 
from canonical SMO-dependent HH signaling. Various 
molecular cues and genetic alterations responsible for 
SMO-independent GLI activation in cancer cells have 
been identified. Oncogenic receptor tyrosine kinases, 
RAS/MAP kinase, PI3K/AKT/S6K, DYRK1A, PKC 
and histone deacetylases can enhance the transcriptional 
activity of GLI in human cancer cells [15-21]. Likewise, 
genetic loss of SUFU results in constitutive GLI activation 
independent of SMO signaling [22]. In pancreatic cancer, 
TGFβ/SMAD signaling is able to induce expression of 
GLI activator forms [23] and in Ewing Sarcoma the EWS-
FLI1 oncogene directly stimulates GLI1 expression [24]. 
GLI proteins, particularly GLI1, act as potent 
oncogenic drivers by promoting a variety of malignant 
traits including proliferation, survival, invasion and 
metastasis (reviewed in [7]). GLI1 also represents a 
critical determinant of tumor-initiating cancer stem cells in 
several entities such as glioblastoma, colorectal cancer and 
pancreatic cancer [16, 25-27]. These oncogenic properties 
together with the capacity of GLI1 to integrate and relay 
common SMO-independent cancer-promoting cues such as 
receptor-tyrosine kinase pathways, PI3K and MAP kinase 
signaling render GLI1 an attractive molecular target for 
cancer therapy. However, unlike kinase inhibition, direct 
targeting of transcription factors is generally considered 
challenging. Some recent studies demonstrated successful 
inhibition, though with yet unclear clinical relevance and 
specificity [28-32].
We therefore turned our focus to kinases as well 
established therapeutic targets to identify druggable 
effectors involved in promoting both canonical and SMO-
independent GLI activation in cancer. Candidate kinases 
include members of the Dual-Specificity Tyrosine-
Phosphorylation-Regulated Kinase (DYRK) family, which 
have been shown to positively and negatively modify HH 
signaling and to have oncogenic functions in solid cancers 
known to be associated with HH/GLI signaling including 
pancreatic cancer [33]. The DYRK family comprises two 
subfamilies with a total of five members [34]. Of note, the 
class I DYRK family member DYRK1A is able to enhance 
GLI1 activity, while the closely related yet functionally 
distinct class I member DYRK1B has been shown to 
increase HH ligand expression and prevent autocrine 
HH pathway activation [15, 35]. By contrast, the class 
II family member DYRK2 negatively affects HH/GLI 
signaling by triggering the destabilization and degradation 
of GLI2/3 transcription factors (Figure 1A) [36]. Whether 
DYRK family members can serve as therapeutic targets 
in HH/GLI-associated cancer entities has not yet been 
addressed.
In this study we analyzed the role of class I DYRK 
members and identified DYRK1B as critical player in 
both SMO-inhibitor sensitive and resistant settings. 
Furthermore, we introduce a novel small molecule 
DYRK1B inhibitor with potent in vitro and in vivo activity 
targeting GLI dependent cancer cells. We propose that 
small molecule inhibition of DYRK1B represents a novel 
and promising approach to target HH/GLI-associated 
cancers including malignancies with acquired or de novo 
resistance to SMO inhibitors.
RESULTS
Chemical inhibition of class I DYRK members 
impairs HH/GLI pathway activation
Members of the DYRK family can modulate GLI 
activity in opposite directions. While DYRK2 promotes 
GLI degradation [36], overexpression of the class I family 
member DYRK1A is able to promote the transcriptional 
activity of GLI1 (Figure 1A) [15]. Whether small-
molecule modulation of DYRK is able to inhibit HH/GLI 
signaling in cancer cells has not yet been addressed.
To study whether inhibition of DYRK1 kinases 
affects oncogenic HH/GLI signaling, we first measured 
the effect of the known class I DYRK inhibitor harmine 
[37] on HH/GLI pathway activity. As assay system we 
employed HH-responsive, SMO-inhibitor sensitive 
human medulloblastoma cells (DAOY) (Figure 1B) [38] 
and measured changes in the expression of the known HH 
target genes GLI1 and PTCH as quantitative read-out for 
pathway activity. 
Smoothened Agonist (SAG) treatment of DAOY 
cells induced mRNA expression of the HH targets GLI1 
and PTCH, which was effectively repressed by the 
SMO inhibitor vismodegib (vismo) and notably, also 
by the DYRK1 inhibitor harmine in a concentration 
dependent manner with an IC50(harmine) of 10.9 µM (Figure 
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1C, 1D). Similar to vismodegib, harmine prevented 
the accumulation of GLI1 protein in response to SAG 
treatment (Figure 1E), together suggesting that class I 
DYRK family members may serve as targets for HH/GLI 
signal inhibition by non-SMO antagonists.
Identification of DYRK1B as critical effector in 
canonical HH/GLI signaling
The beta-carboline alkaloid harmine is a potent 
inhibitor of both class I family members DYRK1A and 
DYRK1B and of monoamine oxidase-A [37, 39]. To 
validate the involvement of DYRK1 kinases in HH 
pathway regulation and to address whether DYRK1A, 
DYRK1B or both kinases account for the repressive effect 
of harmine on HH/GLI pathway activity, we performed 
genetic RNA-interference mediated perturbation 
experiments in cells with activated canonical HH/GLI 
signaling. In SAG-stimulated human medulloblastoma 
cells, stable, lentiviral shRNA inhibition of DYRK1A 
moderately reduced GLI1 and PTCH mRNA expression 
by 55 and 40 percent, respectively (Figure 2A, 2B). By 
contrast, knockdown of DYRK1B efficiently abolished 
HH target gene expression below levels of unstimulated 
cells. We confirmed the contribution of DYRK1B to 
Figure 1: The DYRK1 inhibitor harmine blocks canonical HH/GLI signaling. A. Evolutionary distance of DYRK family 
members and mode of action of distinct DYRK members on GLI activation (DYRK1A) and GLI degradation (DYRK2). B. DAOY human 
medulloblastoma cells harbor a responsive canonical HH/GLI signaling system. Treatment with the SMO agonist SAG (100nM) results 
in activation of GLI1 expression that is quantitatively abolished in the presence of the clinically approved SMO inhibitor vismodegib 
(vismo) (0.5 µM). Treatment with recombinant sonic HH protein yielded comparable results (data not shown). C. qPCR analysis showing 
repression of GLI1 mRNA (left) and PTCH mRNA expression (right panel) in SAG-stimulated DAOY cells in response to vismodegib 
(0.5 µM) or harmine treatment (10 µM and 20 µM). D. Analysis of concentration-dependent inhibition of HH pathway activity and IC50 
calculation of 10.9 µM for the natural DYRK inhibitor harmine. E. Efficient inhibition of GLI1 protein expression in SAG-stimulated 
DAOY cells either treated with vismodegib (0.5 µM) or harmine (10 µM and 20 µM).
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HH target gene activation with a second, less functional 
shRNA against DYRK1B (shD1B#2) resulting in 
reduction of GLI1 and PTCH mRNA expression by more 
than 50 and 60 percent, respectively, compared to SAG-
stimulated cells transduced with scrambled control shRNA 
(Figure 2A, 2B). Analysis of GLI1 protein expression 
confirmed mRNA expression data. Inhibition of DYRK1A 
moderately reduced GLI1 protein levels in SAG-treated 
DAOY cells, while depletion of DYRK1B efficiently 
eliminated GLI1 protein expression (Figure 2C). 
Reduction of DYRK1B expression using shD1B#2 with 
moderate or shD1B#3 with little functionality repressed 
GLI1 protein expression proportional to the shRNA 
functionality (Figure 2C). RNAi-mediated inhibition of 
DYRK1B did not impair the formation of the primary 
cilium, an antenna-like compartment essential for HH/GLI 
signal transduction [4], suggesting that HH/GLI inhibition 
by DYRK1B targeting is not due to impaired ciliogenesis 
(Figure S1). The requirement of Dyrk1b for Hh/Gli 
signaling was also obvious in murine Ptch-deficient 
BCC cells [40]. Harmine treatment of murine BCC cells 
reduced Gli1 expression in a concentration-dependent 
manner (Figure 2D and Figure S2), and like in human 
medulloblastoma cells, RNAi mediated perturbation of 
Dyrk1b efficiently inhibited Gli1 protein expression, while 
depletion of Dyrk1a did not. Taken together, these data 
identify DYRK1B as druggable target for the inhibition of 
oncogenic HH/GLI signaling.
Targeting DYRK1B inhibits HH/GLI signaling in 
SMO-inhibitor resistant cells
Overcoming de novo and acquired resistance to 
SMO inhibitors is a major challenge in the treatment of 
HH-associated cancers, underlining the high medical 
Figure 2: Genetic perturbation of DYRK1B interferes with canonical HH/GLI pathway activation. A.-B. qPCR analysis 
of GLI1 (A) or PTCH mRNA expression (B) in SAG-treated DAOY cells stably transduced with scrambled control shRNA (shcont), 
shRNA against DYRK1A (shD1A), or two shRNAs against DYRK1B (shD1B#1, shD1B#2). C. Western blot analysis of GLI1 protein 
expression in SAG-stimulated DAOY cells expressing the respective lentiviral shRNA constructs and a third shRNA against DYRK1B 
(shD1B#3). D. Western blot analysis of Ptch-deficient murine BCC cell lines showing abrogation of Gli1 expression by harmine treatment 
(left panel) (10 µM and 20 µM) and by shRNA against Dyrk1b (shD1b) but not by shRNA against Dyrk1a (shD1a) (right panel). Fine black 
lines indicate cropping of intermediate lanes from the same Western blots. ACTB/Actb: human/mouse beta actin loading control.
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Figure 3: DYRK1B targeting inhibits SMO-dependent and SMO-independent activation of GLI. A. Illustration of 
HH/GLI signaling and SMO-targeting in PTCH- or SUFU-deficient cells. In PANC-1 pancreatic cancer cells, TGFb and RAS control 
GLI1 expression independent of SMO. In Ewing sarcoma cells (A673) the EWS-FLI1 oncoprotein directly activates GLI1 expression. 
B. shRNA-mediated depletion of SUFU renders DAOY cells resistant to SMO inhibition by vismodegib (vismo). Western blot analysis 
showing that stable expression of shRNA against SUFU (shSUFU) results in activation of GLI1 expression. Note that GLI1 expression 
in SUFU depleted cells is resistant to SMO inhibition by vismodegib. shcont: scrambled control shRNA. C. Western blot showing GLI1, 
GLI2 and GLI3 expression in wild-type and SUFU-deficient DAOY cells in response to DYRK1A/B knock-down. Note that RNAi against 
DYRK1B (shD1B) but not against DYRK1A (shD1A) strongly reduces GLI1 and moderately reduces GLI2 expression in SUFU-depleted 
(shSUFU) DAOY cells. GLI3 expression and processing are unaffected by DYRK1A and DYRK1B targeting. D. Harmine treatment (10 
µM and 20 µM) inhibits Gli1 protein expression in both Ptch-deficient and Sufu-deficient mouse embryonic fibroblasts (MEF). E. Human 
pancreatic adenocarcinoma cells PANC-1 express detectable levels of GLI1 protein in response to TGFb/SMAD and RAS signaling [23]. 
GLI1 expression in PANC-1 cells is independent of SMO activity since vismodegib (vismo) treatment does not affect GLI1 protein levels 
(left panel). RNAi against GLI1 (shGLI1) and against DYRK1B (shD1B) but not against DYRK1A (shD1A) efficiently represses GLI1 
protein expression. DYRK1B targeting does not affect non-HH/GLI effectors such as STAT5 (or STAT3 and CTNNB, data not shown). 
F. qPCR analysis of PANC-1 cells showing that inhibition of DYRK1B (shD1B#1, shD1B#2) but not of DYRK1A (shD1A) reduces 
expression of the GLI target BCL2. G. GLI1 expression in the Ewing sarcoma cell line A673 harboring the EWS-FLI1 oncogene is resistant 
to SMO inhibition by vismodegib (vismo) treatment (left panel). While shRNA against DYRK1A (shD1A) does not affect GLI1 expression 
in A673 cells, knock down of DYRK1B with two distinct shRNAs (shD1B#1, shD1B#2) decreases GLI1 expression (right panel). shGLI1 
knockdown demonstrates specificity of the anti-GLI1 antibody used for detection of GLI1 in PANC-1 and A673 cells. ACTB/Actb: human/
mouse beta actin loading control. Fine black lines indicate cropping of intermediate lanes from the same Western blots.
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need for HH inhibitors acting independent of SMO. To 
map DYRK1B within the HH/GLI signaling cascade, 
we performed epistasis experiments by using PTCH 
and SUFU-deficient cells displaying SMO-dependent 
and SMO-independent pathway activation, respectively. 
In addition, we analyzed the role of DYRK1B in the 
regulation of GLI1 expression in pancreatic cancer and 
Ewing sarcoma cells, where TGFβ/RAS and the EWS-
FLI1 oncogene, respectively, control GLI1 expression 
independent of canonical SMO activity (Figure 3A) [23, 
24].
As a first approach we triggered SMO-independent 
GLI activation in human medulloblastoma cells (DAOY) 
by RNAi mediated knockdown of SUFU, a critical 
negative GLI regulator acting downstream of SMO (Figure 
3A)[41]. As shown in Figure 3B, SUFU-knockdown in 
DAOY cells led to activation of GLI1 expression that was 
resistant to vismodegib treatment. In contrast to SMO 
inhibition, RNAi-mediated depletion of DYRK1B but 
not of DYRK1A largely prevented GLI1 expression and 
moderately reduced GLI2 expression while leaving levels 
and processing of GLI3 unchanged (Figure 3C). 
We confirmed the role of Dyrk1b in the regulation of 
Gli1 using mouse embryonic fibroblasts (MEF) deficient in 
either Ptch or Sufu. In line with Dyrk1b acting downstream 
of Smo, Dyrk1b inhibition by harmine treatment reduced 
Gli1 expression in Ptch-/- and Sufu-/- MEF (Figure 3D), 
while vismodegib abolished Gli1 expression only in Ptch-
/- but not in Sufu-/- cells (data not shown).
In light of these findings we hypothesized that 
targeting DYRK1B may represent a novel strategy to 
inhibit oncogenic GLI1 activity in cancer cells with non-
canonical, SMO-independent GLI1 activation. As proof 
of concept we tested this hypothesis in pancreatic cancer 
and Ewing sarcoma cell models. Pancreatic cancer cells 
have been shown to express GLI1 in response to TGFβ 
and RAS signaling independent of SMO activation [23, 
42]. To test whether DYRK1B contributes to the control 
of GLI1 expression in pancreatic cancer cells, we analyzed 
PANC-1 cells for GLI1 expression in response to DYRK1 
inhibition. PANC-1 cells display high levels of DYRK1B 
and express detectable levels of GLI1 protein. GLI1 
protein levels remained unaffected upon vismodegib 
treatment, indicating SMO-independent GLI1 regulation 
and de novo resistance to SMO targeting (Figure 3E, left 
panel). Of note, RNAi targeting of DYRK1B but not of 
DYRK1A resulted in loss of GLI1 protein expression and 
in reduced mRNA levels of the GLI1 target BCL2 [43] 
(Figure 3E right panel and 3F).
Ewing sarcoma cells harboring the EWS-FLI1 
oncogenic fusion gene have been shown to express GLI1 
[44] in response to direct binding of the EWS-FLI1 
oncoprotein to the GLI1 promoter. Consequently, EWS 
cells (here A673 cells) display SMO-independent GLI1 
expression that is resistant to vismodegib treatment [24] 
(Figure 3G, left panel). In agreement with the previous 
data in SUFU-deficient and pancreatic cancer cells, 
inhibition of DYRK1B but not of DYRK1A reduced GLI1 
protein levels (Figure 3G, right panel). Together, these 
data identify DYRK1B as possible therapeutic target to 
overcome SMO-inhibitor resistance in GLI1-dependent 
cancer cells.
A novel DYRK1 inhibitor as potent antagonist of 
HH/GLI signaling
Having identified DYRK1B as novel drug target for 
the inhibition of oncogenic HH/GLI signaling, we set out 
to screen for small molecule inhibitors with potent activity 
against DYRK1B and pharmacological properties suitable 
for in vivo administration and therapy.
To identify inhibitors of HH signaling we screened 
in house kinase inhibitors for activity in Shh-light2 
reporter gene assay. This led to the identification of a 
novel DYRK1 inhibitor referred to as DYRKi (Figure 
4A) that inhibited reporter gene activity with an IC50 
of 3.7 µM (Figure 4B) without affecting viability and 
inhibited the target kinase DYRK1B with an IC50 of 90 
nM in extracellular in vitro ATP competition assays using 
recombinant protein (data not shown). The compound 
was shown to be nontoxic, and demonstrated favorable 
selectivity against other kinases in the DiscoveRX 
KINOMEScan (selectivity factor S (35)=0.078) (Figure S3 
A-D). DYRKi demonstrated in vivo a dose proportional 
exposure of up to 100 mg/kg. Administration of 100 mg/
kg resulted in a plasma concentration of ~10 µM over 
8 h, and a terminal t1/2 of ~3 h, demonstrating suitable 
pharmacokinetics for once daily dosage (Figure S3 A, B).
Importantly and in line with our DYRK1B RNAi 
data, DYRKi treatment of SAG-treated SUFU-positive 
(WT MB +SAG) and untreated SUFU-depleted (∆Sufu 
MB) human medulloblastoma cells prevented GLI1 
mRNA expression at comparable IC50 concentrations 
of 1.16 µM and 1.04 µM, respectively (Figure 4C). By 
contrast, vismodegib treatment prevented GLI1 expression 
only in SUFU-positive cells but not in SUFU-depleted 
SMO-inhibitor resistant cells (Figure 4D). DYRKi-
treated cells were viable and fully responsive to non-HH 
stimuli such as EGF, indicating that DYRKi-mediated 
HH-pathway inhibition is not due to unspecific cytotoxic 
effects of the compound (Figure S4). Furthermore, 
DYRKi treatment did not significantly change DYRK1B 
protein levels in DAOY, PANC-1 or A673 cells (Figure 
S5). Analysis of GLI1 protein expression in SUFU-
positive and SUFU-deficient human medulloblastoma 
cells (Figure 4E, 4F) and Sufu knockout mouse embryonic 
fibroblasts (Figure 4G) further corroborated the potent 
activity of DYRKi to inhibit GLI activity in SMO-
inhibitor sensitive and resistant cells. Notable, addition of 
the clinically approved proteasome inhibitor bortezomib 
largely reversed the negative effect of DYRK1 inhibition 
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Figure 4: A novel DYRK1 inhibitor efficiently repressing SMO-dependent and SMO-independent GLI1 expression. 
A. Chemical structure of DYRKi, a novel DYRK1 inhibitor. B. Concentration-dependent inhibition of Hh/Gli signaling in murine Gli 
luciferase reporter cells by DYRKi resulting in an IC50 of 3.7 µM. C. DYRKi efficiently blocks HH pathway activity in both SAG-stimulated 
wild-type human medulloblastoma cells (DAOY, WT MB +SAG) and SMO-inhibitor resistant, SUFU depleted medulloblastoma cells 
(ΔSUFU MB). D. shRNA mediated depletion of SUFU expression renders SAG-stimulated human medulloblastoma cells resistant to SMO 
inhibition by vismodegib (vismo). Data in C and D were calculated as a function of GLI1 mRNA expression in the respective samples. 
GLI1 mRNA expression was determined by qPCR. GLI1 mRNA levels of SAG-treated/solvent controls (wild-type DAOY) or solvent-
only treated SUFU depleted DAOY cells were set to 100 percent. E. GLI1 protein expression in SAG-stimulated DAOY medulloblastoma 
cells treated with SMO-antagonists vismodegib (vismo, 0.5 µM), cyclopamine (cyc, 5 µM) or with DYRK1 inhibitors DYRKi (1 µM and 
5 µM) or harmine (10 µM and 20 µM). F. Inhibition of GLI1 protein expression in SUFU depleted DAOY medulloblastoma (shSUFU) 
cells by DYRKi treatment (1 µM and 5 µM). Note that vismodegib (vismo, 0.5 µM) fails to reduce GLI1 expression. shcont: scrambled 
control shRNA. G. DYRKi treatment (1 µM and 5 µM) represses Gli1 protein expression in both Ptch-deficient and Sufu-deficient mouse 
embryonic fibroblasts isolated from Ptch- and Sufu knockout mice, respectively. Vismodegib (vismo) inhibits Gli1 expression in Ptch-
deficient cells only. H.Treatment with the proteasome inhibitor bortezomib largely reverses the suppressive effect of DYRKi on GLI1 and 
GLI2 protein expression, supporting a model of post-translational regulation of GLI1 and GLI2 stability by DYRK1B. Fine black lines 
indicate cropping of intermediate lanes from the same Western blots. ACTB/Actb: human/mouse beta actin loading control.
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on GLI1 and GLI2 by DYRKi (Figure 4H), suggesting 
that DYRK1B plays a critical role in preventing the 
GLI activator forms GLI1 and GLI2 from proteasome-
mediated degradation, consistent with the documented 
role of DYRK1B in protein stabilization [34]. Since we 
were unable to show direct phosphorylation of GLI1 by 
DYRK1B (data not shown), the detailed mechanisms 
of GLI1 (and GLI2) protein stabilization by DYRK1B 
remain unclear.
DYRK1B targeting impairs oncogenic growth of 
GLI-dependent pancreatic cancer cells
In previous work, others and we have provided 
evidence for a critical tumorigenic role of GLI1 in 
pancreatic cancer cells, including reduced formation 
of tumor-initiating spheroids in vitro and impaired in 
vivo tumor growth [45-47]. Having shown that GLI1 
expression in PANC-1 cells depends on DYRK1B, we 
therefore addressed whether inhibition of DYRK1B is 
able to phenocopy the anti-tumorigenic effect of GLI1 
inhibition in pancreatic cancer cells. We first monitored the 
effect of DYRK1B inhibition on tumor-initiating spheroid 
formation of GLI1-dependent yet SMO-inhibitor resistant 
PANC-1 cells in 3D cultures [46]. As shown in Figure 5A 
and 5B, treatment with the SMO inhibitor vismodegib did 
not affect clonogenic growth, while harmine and DYRKi 
treatment significantly reduced large spheroid formation. 
Pre-treatment of pancreatic cancer cells with DYRKi 
or vismodegib prior to seeding into 3D cultures for 
clonogenic growth assays yielded similar results. Again, 
DYRKi reduced the formation of tumor-initiating spheres 
while vismodegib did not (Figure S6). In agreement with 
the critical role of DYRK1B in GLI1 expression, RNA-
interference against DYRK1B but not against DYRK1A 
inhibited clonogenic growth of GLI1-dependent pancreatic 
cancer cells. Note that neither chemical nor genetic 
inhibition of DYRK1B significantly reduced viability of 
cells in planar cultures and equal numbers of viable cells 
were used in all assays. 
To test the in vivo relevance of these data, we 
performed xenograft assays with two distinct GLI1-
dependent pancreatic cancer cell lines (PANC-1 and 
L3.6pl) [46]. In line with in vitro data, stable knockdown 
of DYRK1B effectively abolished the engraftment 
and in vivo tumor growth of PANC-1 and L3.6pl 
pancreatic cancer cells (Figure 5C, 5D). In addition, oral 
administration of DYRKi significantly reduced in vivo 
tumor growth of pancreatic cancer cells (Figure 5E).
Taken together, these results demonstrate that 
inhibition of DYRK1B efficiently represses GLI1 
expression and reduces the malignant properties of GLI1 
dependent cancer cells including pancreatic cancer cells 
with resistance to SMO inhibitors. 
DISCUSSION
The widespread aberrant activation of HH/GLI 
in human cancers and its causal role in tumor initiation 
and growth explain the attractiveness and rationale of 
targeting HH/GLI signaling in cancer. Most efforts to 
identify selective HH pathway inhibitors have so far 
concentrated on targeting the essential pathway effector 
SMO. In 2012, the FDA approved the first-in class oral 
SMO inhibitor vismodegib for the treatment of advanced 
and metastatic basal cell carcinoma with striking 
therapeutic efficacy, though severe side effects and the 
rapid development of acquired SMO inhibitor resistance 
pose significant limitations to the clinical application of 
drugs targeting SMO [10, 11, 48]. Furthermore, clinical 
trials on colorectal, ovarian and pancreatic cancer failed to 
demonstrate therapeutic efficacy of SMO inhibition [13], 
which may at least in part be due to SMO-independent 
activation of oncogenic GLI activity by for instance 
TGFβ, RAS, PI3K/AKT/S6K or genetic deletion of the 
GLI repressor SUFU (reviewed in [7, 49]). Together, 
these potential shortfalls of SMO inhibitors call for 
the identification of targets regulating oncogenic GLI 
downstream of SMO.
In the present study, we identified DYRK1B as 
cell-autonomous positive regulator of GLI activity. 
We have shown that genetic and chemical perturbation 
of DYRK1B represses the expression of the GLI1 
oncogene in a variety of settings, including human brain 
and pancreatic cancer and murine basal cell carcinoma 
cells. Importantly, DYRK1B targeting abolished GLI1 
expression in SMO-inhibitor sensitive and SMO-inhibitor 
resistant cells including SUFU deficient medulloblastoma, 
GLI1-dependent pancreatic cancer [16, 23] and Ewing 
sarcoma cells expressing GLI1 in response to the EWS-
FLI1 oncoprotein [24, 44]. This places DYRK1B function 
downstream of SMO/SUFU to promote GLI1 oncogene 
expression.
Mechanistically, we propose that D1B enhances the 
stability of GLI activator forms [50], as inhibition of the 
proteasome machinery neutralizes the negative regulatory 
effect of DYRK1B targeting on GLI1/2 expression. 
Whether stabilization of GLI1 and GLI2 involves direct 
phosphorylation by DYRK1B or depends on alternative 
indirect mechanisms is unclear at present and requires 
future in-depth analysis of post-translational GLI 
modifications.
In light of the disappointing outcomes of several 
clinical trials with SMO inhibitors, targeting oncogenic 
GLI transcription factors downstream of SMO has 
emerged as promising alternative therapeutic strategy. 
Other non-SMO Hedgehog pathway inhibitors including 
kinase inhibitors or epigenetic modifiers [19, 31, 51], 
inhibitors of GLI DNA binding and/or post-transcriptional 
GLI activation [28, 30, 52-54], or GLI antagonists with 
yet unidentified targets have recently been reported 
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Figure 5: DYRK1B targeting inhibits the malignant properties of GLI1-dependent human pancreatic cancer cells. A.-
B. Growth of GLI1 expressing PANC-1 spheres in 3-D cultures. Sphere formation is resistant to SMO inhibition by vismodegib (vismo) 
and shRNA against DYRK1A. By contrast, harmine (10 µM and 25 µM), DYRKi (5 µM) and shRNA against DYRK1B (shD1B) efficiently 
prevent the formation of tumor-initiating spheres. Sphere formation shown in A) was quantitatively analyzed and the number of tumor-
initiating (ti) spheres plotted in B). For all experiments, identical numbers of live cells were seeded into 3D matrix cultures. We noted that 
inhibition of DYRK1B does not simply induce cell death but prevents the formation of large spheres formed by highly clonogenic, putative 
tumor-initiating cells [16]. C.-D. Xenograft analysis of in vivo tumor growth of PANC-1 (n=7) in C. and highly metastatic GLI1-dependent 
L3.6pl pancreatic cancer cell lines (n=6) in D. shControl: cells lentivirally transduced with scramble control shRNA, shDYRK1B: cancer 
cells stably expressing shRNA against DYRK1B. E. Oral administration of DYRKi (100 mg/kg/d) significantly reduces in vivo tumor 
growth of GLI1-dependent pancreatic cancer cells (L3.6pl) (n=20). Control mice (n=8) received solvent only (control). * p ≤ 0.05, ** p ≤ 
0.01, *** p ≤ 0.001; 
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[29], supporting the promising therapeutic potential of 
targeting oncogenic GLI transcription factors in settings 
where SMO-inhibition is inefficient. However, except 
for arsenic trioxide and pyrvinium [51, 52, 54], lack of 
suitable pharmacological properties, limited potency or 
toxicity is a concern for many of the GLI antagonists 
identified. The identification of DYRKi as a novel DYRK1 
inhibitor with suitable pharmacokinetics and anti-GLI1 
activity provides proof-of-concept for oncogenic HH/GLI 
inhibition by DYRK1B targeting in malignancies with de 
novo or acquired SMO inhibitor resistance.
Previous studies have already highlighted the 
complex regulatory role of DYRK family members in 
HH/GLI signaling. For instance, DYRK2 can directly 
phosphorylate GLI2 thereby promoting its degradation, 
while overexpression of DYRK1A can enhance GLI 
transcriptional activity. DYRK1B, the closest homologue 
of DYRK1A, can act downstream of RAS to prevent 
autocrine and promote paracrine HH signaling in RAS 
mutant cancer cells [35]. The same study has also shown 
a repressive effect of oncogenic RAS and its downstream 
effector DYRK1B on GLI expression, contrasting our 
findings and those of other independent studies that 
support a GLI-activating role of DYRK1B and RAS, 
respectively [23, 42, 55]. Whether this discrepancy is 
due to different experimental conditions (e.g. serum, 
confluency, cell line passages, transient versus stable long-
term knockdown approaches) is unclear.
Our findings that DYRK1B rather than DYRK1A 
acts as critical positive regulator of HH/GLI add another 
example of HH/GLI regulation by DYRK kinases with 
possible therapeutic relevance and also highlight the 
highly complex and context-dependent control of HH/
GLI activity [7].
Using SMO-inhibitor resistant pancreatic cancer 
cells we also confirm a previous report showing that 
DYRK1B targeting in pancreatic cancer cells has 
pronounced therapeutic efficacy in vitro and in vivo, 
though the molecular mechanisms including the link to 
HH/GLI signaling remained unidentified in this study 
[56]. In the present study we show that interfering with 
DYRK1B dramatically impairs SMO-independent GLI1 
expression in RAS mutant pancreatic cancer cells and 
phenocopies the anti-tumorigenic effect of GLI1 targeting 
[16]. Since GLI activator function is critical for tumor-
initiating cells [16, 25, 25, 57] and also involved in the 
development of Ras-driven murine pancreatic cancer 
within the epithelial tumor compartment [23, 47, 55], 
we speculate that chemical DYRK1B inhibition may be 
able to repress the growth of pancreatic cancer due to 
negative regulation of SMO-independent GLI1 in tumor 
and tumor-initiating cells, consistent with the abrogation 
of tumor engraftment in response to genetic DYRK1B 
inhibition. Intriguingly, up to 10 percent of pancreatic 
cancers harbor genomic amplifications of DYRK1B 
and display DYRK1B overexpression in the epithelial 
compartment of the tumors [33]. Targeting DYRK1B may 
therefore overcome the inefficient therapeutic response of 
pancreatic cancer patients to SMO-inhibitors that target 
canonical paracrine signaling in the tumor environment 
rather than non-canonical GLI activity in the epithelial 
tumor compartment [58-61]. It will be important to address 
in future studies whether DYRK1B overexpression and 
amplification correlate with increased epithelial GLI1 
protein levels and therapeutic response to DYRK1B 
inhibition in patient samples.
In summary, the identification of DYRK1B as drug 
target for the inhibition of oncogenic HH/GLI signaling 
in SMO-inhibitor resistant cancers and the introduction 
of DYRKi as novel DYRK1B inhibitor with suitable 
pharmacologic properties provide a basis for future efforts 
to translate these findings to clinical testing.
MATERIALS AND METHODS
Cell culture and inhibitors
DAOY cells (American Type Culture Collection, 
ATCC, Manassas, VA, USA) were grown as described 
previously [38]. BSZ2 cells were grown as described in 
[40] and PANC-1 (ATCC) cells as described in [46]. 
Ptch-/- and Sufu-/- embryonic fibroblasts were 
grown in DMEM supplemented with 10% fetal bovine 
serum (FBS), antibiotics and for Sufu-/- cells also with 
L-glutamine. During assays and treatments of confluent 
cells, FBS was reduced to 0.5%. For 3-dimensional (3D) 
cultures, 5 x 103 cells were seeded in 12-well plates as 
described previously [62]. 3D spheroid cultures were 
grown for 4-6 weeks at 37°C in a humidified atmosphere 
containing 5% CO2. Colony formation was documented 
on a stereomicroscope with Cell^D Image capture system 
(Olympus, Tokyo, Japan) and quantified using Colony 
Counter Software (Microtec Nition, Chiba, Japan). 
Smoothened agonist SAG (Axxora, Farmingdale NY, 
USA), harmine (Thermo Fisher Scientific, Waltham, 
MA, USA), vismodegib, cyclopamine (LC Laboratories, 
Woburn, MA, USA), GANT61 (Merck Chemicals Ltd., 
Darmstadt, Germany) and DYRKi were dissolved in 
dimethylsulfoxide (DMSO, Sigma, St. Louis, MO, USA).
RNA interference and lentiviral transduction
Stable RNAi knockdown experiments were 
performed by lentiviral shRNA transductions as 
described in [16]. The following shRNA constructs 
selected from the Mission TRC shRNA library (Sigma) 
were used: shRNA DYRK1A (TRCN0000000526), 
shRNA DYRK1B#1 (TRCN0000002139), shRNA 
DYRK1B#2 (TRCN0000355722), shRNA DYRK1B#3 
(TRCN0000355721), shSUFU (TRCN0000019466) and 
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scrambled control shRNA (SHC002) (Sigma). The shGLI1 
construct has been described in [16]. The functionality of 
shRNAs was validated by Western blot analysis using 
antibodies listed below.
RNA isolation, qPCR and Western blot analysis
Total RNA was isolated using TRI-reagent 
(Molecular Research Center Inc., Cincinnati, OH, USA) 
followed by LiCl purification. Precipitated and purified 
RNA was used for cDNA synthesis using Superscript II 
reverse transcriptase (Life Technologies, Thermo Fisher 
Scientific) according to the manufacturer´s instructions. 
qPCR was done on a Rotorgene Q (Qiagen, Venlo, 
Netherlands) using GoTaq qPCR Mastermix reagent 
(Promega, Fitchburg, WI, USA). HH target genes were 
identified with primers as described in [16].
For Western blot analysis, proteins were 
visualized with horseradish peroxidase-conjugated 
secondary antibodies in combination with enhanced 
chemiluminescence detection system (GE Health Care, 
Chalfont St Giles, United Kingdom). The following 
antibodies were used: anti-GLI1 (V812; Cell Signaling 
Technology, Danvers, MA, USA), anti-GLI2 (H-300, 
Santa Cruz Biotechnology, Dallas, TX, USA), anti-GLI3 
(R&D Systems, Minneapolis, MN, USA), anti-DYRK1A, 
anti-DYRK1B (Cell Signaling Technology), anti-SUFU 
(C-15, Santa Cruz Biotechnology), anti-STAT3 (BD 
Biosciences, San Jose, CA, USA), anti-STAT5 (3H7, Cell 
Signaling Technology), anti-Beta Catenin (Cell Signaling 
Technology), anti-ACTB (Santa Cruz Biotechnology)
HH/GLI reporter assays
2.5 x 104 Gli Reporter - NIH3T3 cells (AMS 
Biotechnology Ltd., Abingdon, United Kingdom) 
were seeded per well into a white 96 well plate. After 
overnight incubation, compounds were added for 1h 
prior to HH pathway stimulation with 1 µg/ml murine 
SHH (R&D Systems). After incubation for 24h the cells 
were investigated for viability using CellTiter-FluorTM 
Kit (Promega) and for reporter gene activity using ONE-
Glo™ Luciferase Assay System (Promega).
Identification and synthesis of the DYRK1 
inhibitor DYRKi
We applied the KINOMEscan™ screening platform 
to quantify interactions between test compounds and 
more than 450 human kinases and disease relevant mutant 
variants. The assay was performed at DiscoveRX (San 
Diego, CA, USA) according to the protocol description 
available at http://www.discoverx.com/targets/kinase-
target-biology. The Image shown in Figure S3 was 
generated using TREEspot™ Software Tool and reprinted 
with permission from KINOMEscan®, a division of 
DiscoveRX Corporation (San Diego, CA, USA).
DYRK1B-Kinase Assay was performed at Reaction 
Biology Corporation (Reaction Biology Corp., Malvern, 
PA, USA) according to following protocol. The substrate 
DYRKtide was prepared in fresh Base Reaction Buffer 
(20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 
0.02% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM 
DTT, 1% DMSO) and required cofactors were added. 
Recombinant DYRK1B was added to the substrate 
solution and gently mixed. Compound dilution series in 
DMSO were added to the reaction, followed 20 min later 
by addition of a mixture of ATP and 33P ATP (specific 
activity 0.01 µCi/µl final) to a final concentration of 
10 µM. Reactions were carried out at 25°C for 120 
min, followed by spotting the reactions onto P81 ion 
exchange filter paper. Unbound phosphate was removed 
by extensive washing of the filters in 0.75% phosphoric 
acid. After subtraction of background derived from control 
reactions containing inactive enzyme, kinase activity data 
were expressed as the percent remaining kinase activity in 
test samples compared to vehicle (DMSO) reactions. IC50 
values and curve fits were obtained using Prism (Graph 
Pad Software, La Jolla, CA, USA). 
Synthesis of DYRKi was done as follows: to 
a solution of 2-(2,3-dihydro-1-benzofuran-5-yl)-1,3-
thiazole-4-carboxylic acid (1.00 g. 4.04 mmol) in 
20 ml N,N-dimethylformamide, 5-(trifluoromethyl)-
1H-benzo[d]imidazol-2-amine (895 mg, 4.45 mmol), 
2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium 
hexafluorophosphate (HBTU) (1.53 g, 4.04 mmol), 
4-dimethylaminopyridine (49 mg, 0.40 mmol) and 
N,N-diisopropylethylamine (1.76 ml, 10.11 mmol) 
were added. The reaction mixture was stirred for 72 
h at room temperature, poured into ice water and the 
formed precipitate dried and purified by flash column 
chromatography (DCM/MeOH 95:5 to 0:100). The crude 
product was suspended in Et2O, filtered and dried. The 
product was obtained as a white solid (1.07 g, 2.49 mmol, 
62 % yield). mp: 232.5; 1H NMR (400 MHz, DMSO-d6) 
d 12.51 (bs, 1 H), 11.81 (bs, 1 H), 8.50 (s, 1 H), 8.04 (bs, 
1 H), 7.85 (dd, J=8.33 Hz, J=1.91 Hz, 1 H), 7.77 (bs, 1 
H), 7.62 (d, J=8.34 Hz, 1 H), 7.40 (dd, J=8.46 Hz, J=1.44 
Hz, 1 H), 4.57 (t, J=8.75 Hz, 2 H), 3.16-3.30 (m, 2 H); 
13C NMR (75 MHz, DMSO-d6) d 168.0, 162.1, 159.9, 
148.4, 148.2, 128.6, 127.4, 126.9, 125.8, 125.1, 123.7, 
123.3, 122.1, 121.7, 118.0, 118.0, 117.9, 109.2, 71.7, 28.5; 
analysis (calcd., found for C20H13F3N4O2S): C (55.81, 
55.56), H (3.04, 3.17), F (13.24, 13.1), N (13.02, 12.98), S 
(7.45, 7.18); LC/MS [M+H]+: 431.0.
Xenograft experiments
For in vivo tumor growth studies 1 x 106 PANC-1 or 
1 x 105 L3.6pl pancreatic cancer cells in 25% Matrigel (BD 
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Biosciences) were injected subcutaneously into the lower 
flanks of Foxn1nu nude mice (Charles River Laboratories, 
Wilmington, MA, USA). For in vivo treatment, DYRKi 
was dissolved in sun flower oil and administered at 
100mg/kg/d by oral gavage. Tumor volume was measured 
with a caliper and calculated according to the formula [4/3 
x π x (length/2) x (width/2) x (height/2)].
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